Abstract: Traditional methods of hash production are very labor intensive, and the skills of the individual play a key role in defining the quality of the finished product. Hash production requires multiple steps and lacks automation, and thus, it is not easily scaled and very costly for commercial production. The present disclosure relates to hashish product comprising a cohesive mass of isolated cannabis trichomes and having substantially uniform characteristics and to a process of making same. The process comprises providing isolated cannabis trichomes; mixing the isolated cannabis trichomes under conditions sufficient to obtain a substantially homogeneous resinous mixture; and retrieving at least a portion of the mixture through an extrusion die to obtain the hash product.

Abstract: The present disclosure relates to a cannabinoid composition that has enhanced absorption rates or higher concentrations of the administered cannabinoid into the systemic circulation, the composition comprising at least one cannabinoid and a viscosity modifier present in an effective amount to change the composition from a liquid at about room temperature to a gel upon increase to about body temperature. The disclosure also relates to methods of use of the compositions and cannabinoid products comprising such compositions.

Abstract: The present disclosure relates to cannabinoid compositions that are rehydratable and that upon such rehydration retain at least some of the properties of the original cannabinoid emulsions from which the cannabinoid composition was obtained. In particular, to cannabinoid compositions formed by spray drying of an emulsion, the composition comprising at least one cannabinoid, a carrier oil, one or more emulsifiers, and a sugar carrier, where the composition has a water activity that is less than about 0.5. The emulsion may include a nanoemulsion, a microemulsion, or both a nanoemulsion and a microemulsion. The present disclosure also relates to method of manufacturing same.

Abstract: A dosage device that includes a cannabinoid-containing substance enables controlled addition of the cannabinoid-containing substance to a liquid to produce a cannabinoid-containing liquid for ingestion. In an embodiment, such a dosage device is provided with a container that has a container body holding a liquid and a cover to seal the container body. A dosage device may also or instead be provided with a cover that includes a coupling structure to releasably couple the cover to a liquid container and a seal to seal the container. Other embodiments, including methods of use of a container, methods that involve providing a cannabinoid-containing substance and adding the cannabinoid-containing substance to a cover, and product packages that include multiple covers, are also disclosed.

Abstract: The present disclosure relates to a cannabinoid based emulsification system for infusing a non-aqueous composition with a cannabinoid, the emulsification system comprising: a) at least one cannabinoid in a carrier oil; b) a plurality of emulsifiers having a targeted combined HLB value; and c) a targeted plurality of emulsifiers to oil ratio; wherein b) and c) so that at least 10 wt % of the cannabinoid is solubilized in the oral cavity within 30 minutes after a subject consumes the non-aqueous composition, based on the total weight of the cannabinoid in the non-aqueous composition. Methods of making and using such emulsification systems, and cannabinoid concentrate compositions and cannabis infused non-aqueous compositions comprising such emulsification systems to form beverages, human and pet edibles and confectionaries are also encompassed by the present disclosure.

Abstract: The present disclosure relates to a cannabinoid based dry or aqueous self-emulsification system for infusing a composition with a cannabinoid. The self-emulsification system comprises: a) at least one cannabinoid in a carrier oil; b) a plurality of self-emulsifiers having a targeted combined HLB value; and c) a targeted plurality of self-emulsifiers to oil ratio; wherein b) and c) operate to solubilize at least 1 mg of the cannabinoid in 1 mL of the composition. The dry self-emulsification system is in the form of a self-emulsifiable solid which spontaneously forms an emulsion after the addition of an aqueous medium, whereas the composition spontaneously forms an emulsion upon dilution of the aqueous self-emulsification system with water.

Abstract: The present disclosure relates to a cannabis-infused product, comprising an emulsion containing a cannabinoid profile including one or more cannabinoid, wherein the emulsion is a nanoemulsion. The disclosure also relates to methods of manufacture and of using same.

Abstract: The present disclosure relates to a Cannabis-infused product comprising a cannabinoid profile including one or more cannabinoid, a first composition for controlling onset of the cannabinoid profile and a second composition for controlling offset of the cannabinoid profile in a subject having used the Cannabis-infused product, wherein the second composition has a delayed onset compared to that one of the first composition. The present disclosure also relates to methods of manufacture and of using same.

Abstract: The present disclosure relates to a cannabis-infused product comprising a cannabinoid profile including one or more cannabinoid, a first composition for controlling onset of the cannabinoid profile and a second composition for extending offset of the cannabinoid profile in a subject having used the cannabis-infused product, wherein the second composition has a delayed onset compared to that one of the first composition. The present disclosure also relates to methods of manufacture and of using same.

Abstract: One example of a cannabinoid-containing product includes a cannabinoid-containing liquid for ingestion and an additive for production of a cannabinoid-containing aerosol for inhalation. A container for such a product could include a container body holding the cannabinoid-containing liquid and additive, and a cover to seal the container body. Another type of container includes a container body holding contents that include a liquid for ingestion, a cover to seal the container body, and an aerosolizer packaged with the container to aerosolize a cannabinoid from the contents for airborne delivery of a cannabinoid-containing aerosol for inhalation. Other embodiments, including multi-container packages, uses, and methods of use, are also disclosed.

Abstract: A container that includes a container body holding a cannabinoid-containing liquid for ingestion and an additive for production of a cannabinoid-containing aerosol for inhalation may also include an indicator of an estimate of effect of either or both of the cannabinoid-containing liquid and the cannabinoid-containing aerosol. In some embodiments a dosage device to enable controlled addition of a cannabinoid-containing substance to the liquid to produce a cannabinoid-containing liquid for ingestion includes an indicator of any one or more of: an amount of the cannabinoid-containing substance to be released into the container and an estimated cannabinoid concentration in the cannabinoid-containing liquid. Other embodiments, including product package embodiments with multiple containers or covers and one or more indicators, are also disclosed.

Abstract: The present disclosure relates to a cannabinoid based emulsification system for infusing an aqueous composition with a cannabinoid, the emulsification system comprising: a) a cannabinoid in a carrier oil; b) a plurality of emulsifiers having a targeted combined HLB value; and c) a targeted plurality of emulsifiers to oil ratio; wherein b) and c) operate to solubilize at least 1 mg of the cannabinoid in 1 mL of an aqueous composition. Methods of making and using such emulsification systems, and cannabinoid concentrate compositions and cannabis infused aqueous compositions comprising such emulsification systems to form beverages, human and pet edibles and confectionaries are also encompassed by the present disclosure.

Abstract: The present invention relates to a novel form of cross-linked high amylose starch and processes for its manufacture. Such cross-linked high amylose starch is useful as an excipient in a controlled-release pharmaceutical formulation when compressed with pharmaceutical agent(s) in a tablet. Such cross-linked high amylose starch is prepared by (a) cross-linking and chemical modification of high amylose starch, (b) gelatinization, and (c) drying to obtain a powder of said controlled release excipient. In a preferred embodiment, such cross-linked high amylose starch is prepared in the following steps: (1) granular cross-linking and additional chemical modification (e.g., hydroxypropylation) of high-amylose starch; (2) thermal gelatinization of the starch from step (1); and (3) drying the starch from step (2) to yield a powder capable of being used as a controlled release excipient.

Abstract: The present invention relates to a novel form of cross-linked high amylose starch and processes for its manufacture. Such cross-linked high amylose starch is useful as an excipient in a controlled-release pharmaceutical formulation when compressed with pharmaceutical agent(s) in a tablet. Such cross-linked high amylose starch is prepared by (a) cross-linking and chemical modification of high amylose starch, (b) gelatinization, and (c) drying to obtain a powder of said controlled release excipient. In a preferred embodiment, such cross-linked high amylose starch is prepared in the following steps: (1) granular cross-linking and additional chemical modification (e.g., hydroxypropylation) of high-amylose starch; (2) thermal gelatinization of the starch from step (1); and (3) drying the starch from step (2) to yield a powder capable of being used as a controlled release excipient.

Abstract: The present invention relates to a solid slow release oral pharmaceutical dosage unit resistant to amylase which comprises a solid dosage unit made up of an admixture of a therapeutic dosage of an orally effective pharmaceutical agent, an optional polysaccharide or polyol, and high amylose starch, wherein the cross-linking of the high amylose starch has been carried out with a cross-linking agent with from about 0.1 g to about 40 g of cross-linking agent per 100 g of high amylose starch. In a preferred embodiment of the invention, the high amylose starch is modified with a functional group-attaching reagent that covalently bonds functional groups thereto.

Abstract: The present invention is concerned with a solid slow release oral pharmaceutical dosage unit resistant to amylase which comprises a solid dosage unit made up of an admixture of a therapeutic dosage of an orally effective pharmaceutical product, an optional polysaccharide or polyol, and cross-linked high amylose starch, wherein the cross-linking of the high amylose starch has been carried out with a covalent or non-covalent cross-linking agent with from about 0.1 g to about 30 g of cross-linking agent per 100 g of high amylose starch.

Abstract: Disclosed is a pharmaceutical controlled release tablet containing an active ingredient in combination with a carrier made of cross-linked amylose in which hydroxymethylpropylcellulose (HPMC) with a viscosity higher than or equal to 4000 cps is added as an adjuvant. The addition of HPMC to the tablet permits to control the effect of enzymes, and more particular alpha-amylase present in the intestinal medium, on the cross-linked amylose used as a carrier, and thus to reduce the dependence of the kinetics of release upon the concentration of enzymes present in the medium.